FRLN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 feb 2024 @ 21:37):

Stats
Dagens volum	5 349.00
Gjennomsnittsvolum	28 144.00
Markedsverdi	28.28M
EPS	$0 ( 2024-04-02 )
Neste inntjeningsdato	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.569
ATR14	$0.0640 (0.99%)

Volum Korrelasjon

Lang: -0.38 (neutral)

Kort: 0.00 (neutral)

Signal:(61.011) Neutral

Freeline Therapeutics Korrelasjon

10 Mest positive korrelasjoner
INVZ	0.906
VEEE	0.895
PSTV	0.891
ISUN	0.891
COMM	0.889
MTCH	0.887
DIBS	0.886
BBIG	0.884
ICCC	0.879
NEGG	0.877

10 Mest negative korrelasjoner
TYHT	-0.846
RAM	-0.825
SVFC	-0.82
CPTA	-0.816
ALDX	-0.807
SCR	-0.804
VERX	-0.803
EBSB	-0.803
AAON	-0.802
BLCT	-0.801

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Freeline Therapeutics Korrelasjon - Valuta/Råvare

-0.79
( moderate negative )

-0.74
( moderate negative )

0.00
( neutral )

-0.71
( moderate negative )

-0.15
( neutral )

0.72
( moderate )

Freeline Therapeutics Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$-1.74M (0.00 %)
EPS:	$-22.52

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.74M (0.00 %)
EPS:	$-22.52

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-3.93

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-6.81

Financial Reports:

No articles found.

Freeline Therapeutics

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.